Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck active R&D External Licenses & Collaborations (count)
Merck Impact Report
Latest, FY2025
40
Period ended Dec 31, 2025
Change on a year earlier
-46.7%
75 in FY2024
History
8 years
Since FY2018
Sources
1
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Active R&D External Licenses & Collaborations (count) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 40 | -46.7% | – |
| FY2024 | Dec 31, 2024 | 75 | -1.3% | – |
| FY2023 | Dec 31, 2023 | 76 | -21.6% | – |
| FY2022 | Dec 31, 2022 | 97 | +5.4% | – |
| FY2021 | Dec 31, 2021 | 92 | +17.9% | – |
| FY2020 | Dec 31, 2020 | 78 | +21.9% | – |
| FY2019 | Dec 31, 2019 | 64 | +1,180.0% | – |
| FY2018 | Dec 31, 2018 | 5 | – | – |
Cite this data
StockData. (2026). Merck Active R&D External Licenses & Collaborations (count), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/esg_rd_ext_collabs
See every metric in the Merck KPI table. Data updated Oct 26, 2026.